Isofol And 4D - A Sorry Tale Of Two Battered Biotechs
Under The Shadow Of Liquidation
The fear of going out of business before getting a drug submitted to regulators is one that a couple of European biotechs have had to face up to this week.
You may also be interested in...
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.
The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.
Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.